(Q52207725)

27 April 2018

title

Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials. (English)

1 reference

27 April 2018

author name string

Stuschke M

series ordinal

1

1 reference

27 April 2018

Thames HD

series ordinal

2

1 reference

27 April 2018

publication date

1 May 1999

1 reference

27 April 2018

Radiotherapy and Oncology

published in

1 reference

27 April 2018

volume

51

1 reference

27 April 2018

issue

2

1 reference

27 April 2018

page(s)

113-121

1 reference

27 April 2018

Accelerated versus conventional fractionation in the postoperative irradiation of locally advanced head and neck cancer: influence of tumour proliferation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Hyperfractionation: where do we stand?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Radiobiological considerations in the design of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Clinical radiobiology of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Quantifying the position and steepness of radiation dose-response curves

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Dosimetric Precision Requirements in Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Further analysis of radiobiological parameters from the First and Second British Institute of Radiology randomized studies of larynx/pharynx radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Tumour and normal tissue responses to fractionated non-uniform dose delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Re-analysis of the time factor in local control by radiotherapy of T3T4 squamous cell carcinoma of the larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Alpha/beta value and the importance of size of dose per fraction for late complications in the supraglottic larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Onc

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Radiation dose-response of human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Normal tissue reactions in the British Institute of Radiology Study of 3 fractions per week versus 5 fractions per week in the treatment of carcinoma of the laryngo-pharynx by radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Sensitivity of human squamous cell carcinoma of the larynx to fractionated radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Clinical implications of heterogeneity of tumor response to radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Dose, time, and fraction size issues for late effects in head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Early tumour response and treatment toxicity after hyperfractionated radiotherapy in nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Local control of carcinoma of the tonsil by radiation therapy: An analysis of patterns of fractionation in nine institutions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: Patterns of fractionation study of radiobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

A new isoeffect curve for change in dose per fraction

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900042-0

7 January 2021

10.1016/S0167-8140(99)00042-0

Identifiers

DOI

1 reference

27 April 2018

PubMed ID

10435801

1 reference

27 April 2018